Hims Offers Apotex's Generic Semaglutide in Canada After Novo Patent Expiry

Felix Health offering generic semaglutide to clients across Canada

A major Canadian online health-care platform is providing its customers with access to lower-cost semaglutide, a drug prescribed to treat people with Type 2 diabetes and used by many for weight loss.

Novo Nordisk lets Canadian patent expire

Generic versions of Ozempic went on sale this week in Canada — somehow the world’s second-largest GLP-1 market — raising questions about whether Novo Nordisk’s failure to renew its Canadian patent and prevent the entry of generic companies into the country was a bit of cunning corporate strategy or an expensive oversight.Novo and Eli Lilly have already faced stiff competition from smaller “compounders” of weight-loss drugs. But entry from generi…

Hims offers Apotex’s generic semaglutide in Canada after Novo patent expiry

Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk’s blockbuster drug Ozempic, through its platform.

Hims sells generics for Novo’s semaglutide in Canada (HIMS)

Hims & Hers (HIMS) stock is in focus as the company launches generics targeting Novo Nordisk's (NVO) semaglutide in Canada. Read more here.

Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry

Hims & Hers Health said on Thursday it is now offering Canadians a generic version of ​semaglutide, the active ingredient in Novo Nordisk's blockbuster GLP-1 drugs, through ‌its telehealth platform.

Hims & Hers Launches Generic Semaglutide Access in Canada

Hims & Hers Health, Inc., one of the leading health and wellness platforms, announced on May 21st the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at USD 149/month CAD. GLP-1 treatments have transformed obesity an…